Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase".
作者信息
Chu Chia-Ming, Liaw Yun-Fan
机构信息
Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):510-512. doi: 10.3350/cmh.2023.0018. Epub 2023 Jan 30.
Abstract
摘要
相似文献
1
Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase".关于“慢性乙型肝炎血清免疫耐受期的长期预后及组织学评估的必要性”的信函
Clin Mol Hepatol. 2023 Apr;29(2):510-512. doi: 10.3350/cmh.2023.0018. Epub 2023 Jan 30.
2
Correspondence on Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase".关于“血清学免疫耐受期慢性乙型肝炎的长期预后及组织学评估需求”信件的通信
Clin Mol Hepatol. 2023 Apr;29(2):513-515. doi: 10.3350/cmh.2023.0044. Epub 2023 Feb 15.
3
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.慢性乙型肝炎血清学免疫耐受期的长期预后和组织学评估的必要性。
Clin Mol Hepatol. 2023 Apr;29(2):482-495. doi: 10.3350/cmh.2022.0322. Epub 2023 Jan 5.
4
Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?".关于“肝活检对于确定慢性乙型肝炎免疫耐受期是否必不可少？”的信函
Clin Mol Hepatol. 2023 Jul;29(3):812. doi: 10.3350/cmh.2023.0132. Epub 2023 May 8.
5
Unresolved issues of immune tolerance in chronic hepatitis B.慢性乙型肝炎免疫耐受未解决的问题。
J Gastroenterol. 2020 Apr;55(4):383-389. doi: 10.1007/s00535-020-01665-z. Epub 2020 Feb 3.
6
Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?".关于“肝活检对于识别慢性乙型肝炎免疫耐受期是否必不可少？”的信件往来
Clin Mol Hepatol. 2023 Jul;29(3):820. doi: 10.3350/cmh.2023.0135. Epub 2023 May 19.
7
Histologic changes in immune-tolerant patients with chronic hepatitis B: a systematic review and meta-analysis.免疫耐受慢性乙型肝炎患者的组织学变化：系统评价和荟萃分析。
Sci Rep. 2023 Jan 10;13(1):469. doi: 10.1038/s41598-023-27545-z.
8
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise.免疫耐受型慢性乙型肝炎的模仿者：一个伪装的杀手。
Clin Mol Hepatol. 2023 Apr;29(2):363-366. doi: 10.3350/cmh.2023.0079. Epub 2023 Mar 9.
9
Characterization of hepatitis B virus molecular genotypes in Chongqing and quantitative serological markers in patients during natural phases of chronic hepatitis B infection.重庆地区乙型肝炎病毒分子基因型特征及慢性乙型肝炎自然感染期患者血清学标志物定量分析。
Intervirology. 2012;55(1):68-72. doi: 10.1159/000323524. Epub 2011 Feb 5.
10
Prognosis of immune-tolerant phase chronic hepatitis B.免疫耐受期慢性乙型肝炎的预后
Gut. 2018 May;67(5):988. doi: 10.1136/gutjnl-2017-315603. Epub 2017 Nov 25.
引用本文的文献
1
Correspondence on Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase".关于“血清学免疫耐受期慢性乙型肝炎的长期预后及组织学评估需求”信件的通信
Clin Mol Hepatol. 2023 Apr;29(2):513-515. doi: 10.3350/cmh.2023.0044. Epub 2023 Feb 15.
本文引用的文献
1
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.慢性乙型肝炎血清学免疫耐受期的长期预后和组织学评估的必要性。
Clin Mol Hepatol. 2023 Apr;29(2):482-495. doi: 10.3350/cmh.2022.0322. Epub 2023 Jan 5.
2
Management of Older Patients With Immunotolerant Chronic Hepatitis B Infection.免疫耐受期慢性乙型肝炎感染老年患者的管理
Clin Gastroenterol Hepatol. 2023 Jul;21(7):1968-1969. doi: 10.1016/j.cgh.2022.08.039. Epub 2022 Sep 8.
3
Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection.老年免疫耐受慢性乙型肝炎病毒感染者的特征。
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1503-1512.e4. doi: 10.1016/j.cgh.2022.06.015. Epub 2022 Jul 16.
4
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.对于慢性乙型肝炎患者，生物标志物定义的免疫耐受期发生肝细胞癌的风险可忽略不计。
Clin Mol Hepatol. 2021 Apr;27(2):295-304. doi: 10.3350/cmh.2020.0216. Epub 2020 Dec 3.
5
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.慢性乙型肝炎严格定义的未经治疗免疫耐受期内 HCC 风险可忽略不计。
Eur J Intern Med. 2021 Feb;84:68-73. doi: 10.1016/j.ejim.2020.10.022. Epub 2020 Dec 4.
6
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.在免疫耐受期的慢性乙型肝炎患者中，肝细胞癌发展的风险极低。
Aliment Pharmacol Ther. 2020 Jul;52(1):196-204. doi: 10.1111/apt.15741. Epub 2020 May 26.
7
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
8
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
9
A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.一项大型人群组织学研究表明，慢性乙型肝炎中丙氨酸氨基转移酶（ALT）升高与显著纤维化之间缺乏关联。
PLoS One. 2012;7(2):e32622. doi: 10.1371/journal.pone.0032622. Epub 2012 Feb 28.
10
Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase.中国免疫耐受期慢性乙型肝炎患者的自然史和疾病进展
Hepatology. 2007 Aug;46(2):395-401. doi: 10.1002/hep.21724.
Zotero 插件